Trials / Active Not Recruiting
Active Not RecruitingNCT06734078
An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study designobservational, non-interventional, retrospective, multicenter study.
Detailed description
The study focusing on information about the effectiveness and safety of polatuzumab vedotin plus rituximab (± bendamustine) in patients who received at least one dose of polatuzumab vedotin plus rituximab (± bendamustine) under the NPP (D.M. 7 Sep 2017) programme in the period between June 2019 and Feb 2020 in Italy.
Conditions
Timeline
- Start date
- 2021-05-20
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2024-12-16
- Last updated
- 2025-01-29
Locations
9 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT06734078. Inclusion in this directory is not an endorsement.